In the past week, TEVA stock has gone up by 4.57%, with a monthly gain of 19.56% and a quarterly surge of 0.59%. The volatility ratio for the week is 5.62%, and the volatility levels for the last 30 days are 4.33% for Teva- Pharmaceutical Industries Ltd. ADR. The simple moving average for the past 20 days is 12.13% for TEVA’s stock, with a -3.40% simple moving average for the past 200 days.
Is It Worth Investing in Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Right Now?
The 36-month beta value for TEVA is also noteworthy at 0.60. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for TEVA is 1.15B, and at present, short sellers hold a 2.48% of that float. The average trading volume of TEVA on May 12, 2025 was 12.45M shares.
TEVA) stock’s latest price update
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA)’s stock price has gone decline by -6.31 in comparison to its previous close of 18.07, however, the company has experienced a 4.57% increase in its stock price over the last five trading days. seekingalpha.com reported 2025-05-08 that Teva’s betting big on biosimilars and specialty drugs, with AUSTEDO and UZEDY leading the charge. Management’s $700 million cost-cutting plan is on track, aiming for a 30% operating margin by 2027. Recent FDA wins, like SELARSDI, show Teva’s pushing into high-margin markets.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with Argus repeating the rating for TEVA by listing it as a “Buy.” The predicted price for TEVA in the upcoming period, according to Argus is $20 based on the research report published on July 10, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $14. The rating they have provided for TEVA stocks is “Neutral” according to the report published on March 08th, 2024.
Piper Sandler gave a rating of “Overweight” to TEVA, setting the target price at $19 in the report published on February 12th of the previous year.
TEVA Trading at 10.53% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.75% of loss for the given period.
Volatility was left at 4.33%, however, over the last 30 days, the volatility rate increased by 5.62%, as shares surge +32.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.74% upper at present.
During the last 5 trading sessions, TEVA rose by +4.57%, which changed the moving average for the period of 200-days by -0.12% in comparison to the 20-day moving average, which settled at $15.10. In addition, Teva- Pharmaceutical Industries Ltd. ADR saw -23.19% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Sabag Mark, who proposed sale 337,915 shares at the price of $18.04 back on May 08 ’25. After this action, Sabag Mark now owns shares of Teva- Pharmaceutical Industries Ltd. ADR, valued at $6,097,324 using the latest closing price.
Daniell Richard, the Exec. VP, European Commercial of Teva- Pharmaceutical Industries Ltd. ADR, sale 70,961 shares at $15.91 during a trade that took place back on Mar 05 ’25, which means that Daniell Richard is holding 48,384 shares at $1,128,642 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- -0.02 for the present operating margin
- 0.49 for the gross margin
The net margin for Teva- Pharmaceutical Industries Ltd. ADR stands at -0.1. The total capital return value is set at -0.01. Equity return is now at value -18.98, with -3.17 for asset returns.
Based on Teva- Pharmaceutical Industries Ltd. ADR (TEVA), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 3.36. The interest coverage ratio of the stock is -0.3.
Currently, EBITDA for the company is 716.0 million with net debt to EBITDA at 19.02. When we switch over and look at the enterprise to sales, we see a ratio of 2.1. The receivables turnover for the company is 5.41for trailing twelve months and the total asset turnover is 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.
Conclusion
In summary, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
